Cadrenal Therapeutics, Inc. plans to submit a Rare Pediatric Disease Designation (RPDD) request to the U.S. Food and Drug Administration (FDA) for tecarfarin as a treatment for pediatric patients with Kawasaki disease (KD) who develop coronary artery aneurysms (CAAs) and require chronic oral anticoagulation. The company aims to present its Phase 3-ready pipeline and pediatric rare-disease expansion strategy to global pharmaceutical partners at the 2026 BIO International Convention in San Diego. If the designation is granted and tecarfarin is approved for this indication, Cadrenal would be eligible to receive a Priority Review Voucher, with recent open-market valuations ranging from $180 million to $205 million.

Kawasaki disease is the leading cause of acquired heart disease in children in developed nations. Up to 25% of untreated children with KD develop enlarged coronary arteries or CAAs. Patients with large CAAs are at risk for forming blood clots, with a continuing lifelong risk for subsequent heart attacks and sudden cardiac death, and require chronic, precise anticoagulation therapy to reduce their higher risk of clot formation.

Tecarfarin is a novel, next-generation Vitamin K antagonist (VKA) designed to overcome limitations of warfarin metabolism and potentially provide more reliable and consistent anticoagulation. "Children with large or giant aneurysms due to KD represent an important underserved orphan population," said Quang X. Pham, Chief Executive Officer of Cadrenal Therapeutics. "The current standard of care – warfarin - is notoriously unstable in children because of dietary variations, concurrent medications, and genetic differences in liver metabolism. Tecarfarin is metabolized in a completely different way than warfarin, and is being developed to offer a highly stable, predictable alternative."

The FDA's RPDD program targets serious or life-threatening diseases that primarily affect fewer than 200,000 people in the United States from birth through age 18. The transferable Priority Review Vouchers can be used to accelerate the FDA review of a future drug or sold to another pharmaceutical manufacturer. Congress has extended the pediatric PRV program through September 30, 2029.

At the BIO International Convention, Cadrenal will present a dual-track portfolio strategy. The Global Pharma Track focuses on CAD-1005, a first-in-class 12-LOX inhibitor that is Phase 3-ready for Heparin-Induced Thrombocytopenia (HIT) and advancing into a Phase 2a trial for Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI). The Regional & Rare Disease Track focuses on tecarfarin for Kawasaki disease, offering strong geographic synergy for Japanese and East Asian pharmaceutical companies where the incidence of the disease is historically 10 to 15 times higher than in Western nations.

Cadrenal Therapeutics, Inc. plans to initiate a Phase 2a proof-of-concept clinical trial of CAD-1005 to prevent acute kidney injury (AKI) in high-risk patients undergoing cardiac surgery. The trial is expected to begin later this year and targets Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI), a serious complication affecting 35,000 U.S. patients annually. Currently, there are no FDA-approved targeted therapies for this condition, representing a significant unmet medical need in a market estimated at $1 billion annually.

The planned study aims to expand the clinical evaluation of CAD-1005 into an acute-care setting while generating data relevant to Cadrenal's lead Phase 3-ready program in heparin-induced thrombocytopenia (HIT). HIT is an immune response to the blood thinner heparin, resulting in blood clots that can cause death, amputation, stroke, and increased healthcare costs. The Phase 2a trial is designed to generate safety data, renal injury signals, and 12-LOX pathway biology in high-risk cardiac surgery patients.

Strategic Development and Collaboration

The development of CAD-1005 for CSA-AKI represents a new high-value indication for the Phase 3-ready asset. Cadrenal expects the data to support clinical development and strategic partnering discussions. The Company is positioned to leverage shared in-hospital ICU infrastructure and an intravenous (IV) formulation to create a turnkey critical care franchise for a global pharmaceutical partner.

Cadrenal intends to discuss the CSA-AKI clinical plan, its implications for CAD-1005's broader development strategy, and potential non-dilutive collaboration opportunities at the BIO International Convention. The initiative is designed to maximize the valuation of the 12-LOX platform ahead of these strategic meetings.

Key Indication Details